Clicky

Hutchison China Ltd(HMDCF) News

Date Title
Oct 1 HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years
Jul 29 HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
Feb 2 HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
Feb 1 HUTCHMED to Announce 2023 Final Results
Jan 30 HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
Jan 11 HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
Dec 13 HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
Dec 13 HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Dec 1 HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
Nov 10 Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Nov 9 HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
Aug 3 HUTCHMED (China) First Half 2023 Earnings: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)